Male breast cancer: Risk factors, biology, diagnosis,treatment, and survivorship

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1434-1443

  Ruddy, K J ^a   Winer, E P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Breast neoplasms; Drug therapy; Etiology; Male; Survivors

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DRUG CONTRAINDICATION; DRUG EFFICACY; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENETIC COUNSELING; HUMAN; MALE BREAST; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORCHIECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOSURGERY; SENTINEL LYMPH NODE BIOPSY; SEX DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; DRUG THERAPY; ETIOLOGY; MALE; SURVIVORS;

AGE FACTORS; BREAST NEOPLASMS, MALE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIFE STYLE; MALE; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84878446230     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt025     Document Type: Article

References (222)

1. Hodgson NC, Button JH, Franceschi D et al. Male breast cancer: is the incidence increasing? Ann Surg Oncol 2004; 11(8): 751-755.
2. Stang A, Thomssen C. Decline in breast cancer incidence in the United States: what about male breast cancer? Breast Cancer Res Treat 2008; 112(3): 595-596.
3. Contractor KB, Kaur K, Rodrigues GS et al. Male breast cancer: is the scenario changing. World J Surg Oncol 2008; 6: 58.
4. Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treat 2009; 115(2): 429-430.
5. White J, Kearins O, Dodwell D et al. Male breast carcinoma: increased awareness needed. Breast Cancer Res 2011; 13(5): 219.
6. Salehi A, Zeraati H, Mohammad K et al. Survival of male breast cancer in Fars, South of Iran. Iran Red Crescent Med J 2011; 13(2): 99-105.
7. Tawil AN, Boulos FI, Chakhachiro ZI et al. Clinicopathologic and immunohistochemical characteristics of male breast cancer: a single center experience. Breast J 2012; 18(1): 65-68.
8. Brinton LA, Richesson DA, Gierach GL et al. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 2008; 100(20): 1477- 1481.
9. Johnson KC, Pan S, Mao Y. Risk factors for male breast cancer in Canada, 1994-1998. Eur J Cancer Prev 2002; 11(3): 253-263.
10. Ewertz M, Holmberg L, Tretli S et al. Risk factors for male breast cancer-a case-control study from Scandinavia. Acta Oncol 2001; 40(4): 467-471.
11. D'Avanzo B, La Vecchia C. Risk factors for male breast cancer. Br J Cancer 1995; 71(6): 1359-1362.
12. Lenfant-Pejovic MH, Mlika-Cabanne N, Bouchardy C et al. Risk factors for male breast cancer: a Franco-Swiss case-control study. Int J Cancer 1990; 45(4): 661-665.
13. Olsson H, Ranstam J. Head trauma and exposure to prolactin-elevating drugs as risk factors for male breast cancer. J Natl Cancer Inst 1988; 80(9): 679-683.
14. Satram-Hoang S, Moran EM, Anton-Culver H et al. A pilot study of male breast cancer in the Veterans Affairs healthcare system. J Environ Pathol Toxicol Oncol 2010; 29(3): 235-244.
15. Ottini L, Masala G, D'Amico C et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res 2003; 63(2): 342-347.
16. Ottini L, Rizzolo P, Zanna I et al. BRCA1/BRCA2 mutation status and clinicalpathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. Breast Cancer Res Treat 2009; 116(3): 577-586.
17. Palli D, Falchetti M, Masala G et al. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy. BMC Cancer 2007; 7: 170.
18. Struewing JP, Coriaty ZM, Ron E et al. Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet 1999; 65(6): 1800-1802.
19. Kwiatkowska E, Teresiak M, Lamperska KM et al. BRCA2 germline mutations in male breast cancer patients in the Polish population. Hum Mutat 2001; 17(1): 73.
20. Syrjakoski K, Kuukasjarvi T, Waltering K et al. BRCA2 mutations in 154 Finnish male breast cancer patients. Neoplasia 2004; 6(5): 541-545. 21. Besic N, Cernivc B, de Greve J et al. BRCA2 gene mutations in Slovenian male breast cancer patients. Genet Test 2008; 12(2): 203-209.
21. Besic N, Cernivc B, de Greve J et al. BRCA2 gene mutations in Slovenian male breast cancer patients. Genet Test 2008; 12(2): 203-209.
22. Kwiatkowska E, Teresiak M, Breborowicz D et al. Somatic mutations in the BRCA2 gene and high frequency of allelic loss of BRCA2 in sporadic male breast cancer. Int J Cancer 2002; 98(6): 943-945.
23. Evans DG, Bulman M, Young K et al. BRCA1/2 mutation analysis in male breast cancer families from North West England. Fam Cancer 2008; 7(2): 113-117.
24. Gilbert SF, Soliman AS, Karkouri M et al. Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients. Breast Dis 2011; 33(1): 17-26.
25. Haraldsson K, Loman N, Zhang QX et al. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 1998; 58(7): 1367-1371.
26. Prechtel D, Werenskiold AK, Prechtel K et al. Frequent loss of heterozygosity at chromosome 13q12-13 with BRCA2 markers in sporadic male breast cancer. Diagn Mol Pathol 1998; 7(1): 57-62.
27. Evans DG, Susnerwala I, Dawson J et al. Risk of breast cancer in male BRCA2 carriers. J Med Genet 2010; 47(10): 710-711.
28. Tai YC, Domchek S, Parmigiani G et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2007; 99(23): 1811-1814.
29. Basham VM, Lipscombe JM, Ward JM et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002; 4(1): R2.
30. Couch FJ, Farid LM, DeShano ML et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996; 13(1): 123-125.
31. Friedman LS, Gayther SA, Kurosaki T et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997; 60(2): 313-319.
32. Falchetti M, Lupi R, Rizzolo P et al. BRCA1/BRCA2 rearrangements and CHEK2* common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat 2008; 110(1): 161-167.
33. Wasielewski M, den Bakker MA, van den Ouweland A et al. CHEK2* 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat 2009; 16(2): 397-400.
34. Ding YC, Steele L, Kuan CJ et al. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat 2011; 126(3): 771-778.
35. Ohayon T, Gal I, Baruch RG et al. CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 2004; 108(3): 479-480.
36. Syrjakoski K, Kuukasjarvi T, Auvinen A et al. CHEK2* 1100delC is not a risk factor for male breast cancer population. Int J Cancer 2004; 108(3): 475-476.
37. Blanco A, de la Hoya M, Balmana J et al. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer. Breast Cancer Res Treat 2012; 132(1): 307-315.
38. Gilbert SF, Soliman AS, Iniesta M et al. Androgen receptor polyglutamine tract length in Egyptian male breast cancer patients. Breast Cancer Res Treat 2011; 129(2): 575-581.
39. Young IE, Kurian KM, Annink C et al. A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer 1999; 81(1): 141-143.
40. Silvestri V, Rizzolo P, Zanna I et al. PALB2 mutations in male breast cancer: a population-based study in Central Italy. Breast Cancer Res Treat 2010; 122(1): 299-301.
41. Young IE, Kurian KM, Mackenzie MA et al. The CAG repeat within the androgen receptor gene in male breast cancer patients. J Med Genet 2000; 37(2): 139-140.
42. Sauty de Chalon A, Teo Z, Park DJ et al. Are PALB2 mutations associated with increased risk of male breast cancer? Breast Cancer Res Treat 2010; 121(1): 253-255.
43. Silvestri V, Rizzolo P, Falchetti M et al. Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy. Breast Cancer Res Treat 2011; 126(2): 539-543.
44. Silvestri V, Rizzolo P, Falchetti M et al. Mutation screening of RAD51C in male breast cancer patients. Breast Cancer Res 2011; 13(1): 404.
45. Kizildag S, Gulsu E, Bagci O et al. Vitamin D receptor gene polymorphisms and male breast cancer risk in Turkish population. J BUON 2011; 16(4): 640-645.
46. Hultborn R, Hanson C, Kopf I et al. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res 1997; 17(6D): 4293-4297.
47. Brinton LA, Carreon JD, Gierach GL et al. Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. Breast Cancer Res Treat 2010; 119(1): 185-192.
48. Medras M, Filus A, Jozkow P et al. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat 2006; 96(3): 263-265.
49. Altinli E, Gorgun E, Karabicak I et al. Anthropometric measurements in male breast cancer. Obesity surgery 2002; 12(6): 869-870.
50. Casagrande JT, Hanisch R, Pike MC et al. A case-control study of male breast cancer. Cancer Res 1988; 48(5): 1326-1330.
51. Hsing AW, McLaughlin JK, Cocco P et al. Risk factors for male breast cancer (United States). Cancer Causes Control 1998; 9(3): 269-275.
52. Lee SC, Ellis RJ. Male breast cancer during finasteride therapy. J Natl Cancer Inst 2004; 96(4): 338-339.
53. Yoneda S, Yoshikawa M, Yamane Y et al. Breast cancer developed in a male patient with liver cirrhosis bearing hepatocellular carcinoma. Am J Gastroenterol 2000; 95(2): 556-557.
54. Thellenberg C, Malmer B, Tavelin B et al. Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol 2003; 169(4): 1345-1348.
55. Petridou E, Giokas G, Kuper H et al. Endocrine correlates of male breast cancer risk: a case-control study in Athens, Greece. Br J Cancer 2000; 83(9): 1234-1237.
56. Rosenblatt KA, Thomas DB, Jimenez LM et al. The relationship between diet and breast cancer in men (United States). Cancer Causes Control 1999; 10(2): 107-113.
57. Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 1993; 53(4): 538-549.
58. Ndom P, Um G, Bell EM et al. A meta-analysis of male breast cancer in Africa. Breast 2012; 21(3): 237-241.
59. Amir H, Hirji KF. Carcinoma of the male breast in Tanzania. J Natl Med Assoc 1992; 84(4): 337-340.
60. Anderson WF, Jatoi I, Tse J et al. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 2010; 28(2): 232-239.
61. Vaizey C, Burke M, Lange M. Carcinoma of the male breast-a review of 91 patients from the Johannesburg Hospital breast clinics. S Afr J Surg 1999; 37 (1): 6-8.
62. Matanoski GM, Breysse PN, Elliott EA. Electromagnetic field exposure and male breast cancer. Lancet 1991; 337(8743): 737.
63. Tynes T, Andersen A. Electromagnetic fields and male breast cancer. Lancet 1990; 336(8730): 1596.
64. Rosenbaum PF, Vena JE, Zielezny MA et al. Occupational exposures associated with male breast cancer. Am J Epidemiol 1994; 139(1): 30-36.
65. Hansen J. Elevated risk for male breast cancer after occupational exposure to gasoline and vehicular combustion products. Am J Ind Med 2000; 37(4): 349-352.
66. Palli D, Masala G, Mariani-Costantini R et al. A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer? Eur J Cancer 2004; 40(16): 2474-2479.
67. Villeneuve S, Cyr D, Lynge E et al. Occupation and occupational exposure to endocrine disrupting chemicals in male breast cancer: a case-control study in Europe. Occup Environ Med 2010; 67(12): 837-844.
68. Stenlund C, Floderus B. Occupational exposure to magnetic fields in relation to male breast cancer and testicular cancer: a Swedish case-control study. Cancer Causes Control 1997; 8(2): 184-191.
69. Cocco P, Figgs L, Dosemeci M et al. Case-control study of occupational exposures and male breast cancer. Occup Environ Med 1998; 55(9): 599-604.
70. Arslan UY, Oksuzoglu B, Ozdemir N et al. Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol 2012; 29(2): 554-560.
71. Chung HC, Kim DL, Koh EH et al. Expression of prognostic factors (EGFR, ER) by immunohistochemical staining method in male breast cancer. Yonsei Med J 1991; 32(2): 126-130.
72. Fox SB, Rogers S, Day CA et al. Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. J Pathol 1992; 166(1): 13-18.
73. Dawson PJ, Paine TM, Wolman SR. Immunocytochemical characterization of male breast cancer. Mod Pathol 1992; 5(6): 621-625.
74. Rogers S, Day CA, Fox SB. Expression of cathepsin D and estrogen receptor in male breast carcinoma. Hum Pathol 1993; 24(2): 148-151.
75. Borgen P.I., Senie RT, McKinnon WM et al. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol 1997; 4(5): 385-388.
76. Moore J, Friedman MI, Gansler T et al. Prognostic indicators in male breast carcinoma. Breast J 1998; 4(4): 261-269.
77. Culell P, Solernou L, Tarazona J et al. Male breast cancer: a multicentric study. Breast J 2007; 13(2): 213-215.
78. Park S, Kim JH, Koo J et al. Clinicopathological characteristics of male breast cancer. Yonsei Med J 2008; 49(6): 978-986.
79. Sharif MA, Mamoon N, Arif A et al. Histological and immuno-histochemical study of male breast carcinoma in Northern Pakistan. J Pak Med Assoc 2009; 59(2): 67-71.
80. El-Habbash MM, Alwindi AA. Male breast cancer in Tripoli, Libya. Saudi Med J 2009; 30(8): 1060-1062.
81. Liukkonen S, Saarto T, Maenpaa H et al. Male breast cancer: a survey at the Helsinki University Central Hospital during 1981-2006. Acta Oncol 2010; 49 (3): 322-327.
82. Burga AM, Fadare O, Lininger RA et al. Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases. Virchows Arch 2006; 449(5): 507-512.
83. Cunha F, Andre S, Soares J. Morphology of male breast carcinoma in the evaluation of prognosis. Pathol Res Pract 1990; 186(6): 745-750.
84. Jonasson JG, Agnarsson BA, Thorlacius S et al. Male breast cancer in Iceland. Int J Cancer 1996; 65(4): 446-449.
85. Tan PH, Sng IT. Male breast cancer: a retrospective study with immunohistochemical analysis of hormone receptor expression. Pathology 1997; 29(1): 2-6.
86. Tahmasebi S, Akrami M, Omidvari S et al. Male breast cancer; analysis of 58 cases in Shiraz, South of Iran. Breast Dis 2010; 31(1): 29-32.
87. Nahleh ZA, Srikantiah R, Safa M et al. Male breast cancer in the Veterans Affairs population: a comparative analysis. Cancer 2007; 109(8): 1471-1477.
88. Anderson WF, Althuis MD, Brinton LA et al. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004; 83(1): 77-86.
89. Leach IH, Ellis IO, Elston CW. c-erb-B-2 expression in male breast carcinoma. J Clin Pathol 1992; 45(10): 942.
90. Bruce DM, Heys SD, Payne S et al. Male breast cancer: clinico-pathological features, immunocytochemical characteristics and prognosis. Eur J Surg Oncol 1996; 22(1): 42-46.
91. Kornegoor R, Verschuur-Maes AH, Buerger H et al. Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol 2012; 25(3): 398-404.
92. Rudlowski C, Friedrichs N, Faridi A et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004; 84(3): 215-223.
93. Ge Y, Sneige N, Eltorky MA et al. Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res 2009; 11(3): R28.
94. Shaaban AM, Ball GR, Brannan RA et al. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat 2012; 133(3): 949-958.
95. Bloom KJ, Govil H, Gattuso P et al. Status of HER-2 in male and female breast carcinoma. Am J Surg 2001; 182(4): 389-392.
96. Barlund M, Kuukasjarvi T, Syrjakoski K et al. Frequent amplification and overexpression of CCND1 in male breast cancer. Int J Cancer 2004; 111(6): 968-971.
97. Andre S, Pinto AE, Laranjeira C et al. Male and female breast cancer-differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis. Pathobiology 2007; 74(6): 323-327.
98. Anelli A, Anelli TF, Youngson B et al. Mutations of the p53 gene in male breast cancer. Cancer 1995; 75(9): 2233-2238.
99. Dawson PJ, Schroer KR, Wolman SR. ras and p53 genes in male breast cancer. Mod Pathol 1996; 9(4): 367-370.
100. Curigliano G, Colleoni M, Renne G et al. Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. Ann Oncol 2002; 13(6): 895-902.
101. Serra Diaz C, Vizoso F, Lamelas ML et al. Expression and clinical significance of apolipoprotein D in male breast cancer and gynaecomastia. Br J Surg 1999; 86 (9): 1190-1197.
102. Rayson D, Erlichman C, Suman VJ et al. Molecular markers in male breast carcinoma. Cancer 1998; 83(9): 1947-1955.
103. Pich A, Margaria E, Chiusa L et al. Androgen receptor expression in male breast carcinoma: lack of clinicopathological association. Br J Cancer 1999; 79 (56): 959-964.
104. Kidwai N, Gong Y, Sun X et al. Expression of androgen receptor and prostatespecific antigen in male breast carcinoma. Breast Cancer Res 2004; 6(1): R18-R23.
105. Murphy CE, Carder PJ, Lansdown MR et al. Steroid hormone receptor expression in male breast cancer. Eur J Surg Oncol 2006; 32(1): 44-47.
106. Ferreira M, Mesquita M, Quaresma M et al. Prolactin receptor expression in gynaecomastia and male breast carcinoma. Histopathology 2008; 53(1): 56-61.
107. Rudlowski C, Schulten HJ, Golas MM et al. Comparative genomic hybridization analysis on male breast cancer. Int J Cancer 2006; 118(10): 2455-2460.
108. Tommasi S, Mangia A, Iannelli G et al. Gene copy number variation in male breast cancer by aCGH. Anal Cell Pathol (Amst) 2010; 33(3): 113-119.
109. Tirkkonen M, Kainu T, Loman N et al. Somatic genetic alterations in BRCA2- associated and sporadic male breast cancer. Genes Chromosomes Cancer 1999; 24(1): 56-61.
110. Kornegoor R, Moelans C, Vershuur-Maes A et al. Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 2012.
111. Kornegoor R, Moelans CB, Verschuur-Maes AH et al. Promoter hypermethylation in male breast cancer: analysis by multiplex ligationdependent probe amplification. Breast Cancer Res 2012; 14(4): R101.
112. Johansson I, Nilsson C, Berglund P et al. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Res Treat 2011; 129(3): 747-760.
113. Johansson I, Nilsson C, Berglund P et al. Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies Nacetyltransferase- 1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res 2012; 14(1): R31.
114. Fassan M, Baffa R, Palazzo JP et al. MicroRNA expression profiling of male breast cancer. Breast Cancer Res 2009; 11(4): R58.
115. Callari M, Cappelletti V, De Cecco L et al. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast ancer Res Treat 2011; 127(3): 601-610.
116. Thalib L, Hall P. Survival of male breast cancer patients: population-based cohort study. Cancer Sci 2009; 100(2): 292-295.
117. Winchester DJ. Male breast carcinoma: a multiinstitutional challenge. Cancer 1998; 83(3): 399-400.
118. Xia LP, Zhou FF, Guo GF et al. Chinese female breast cancer patients show a better overall survival than their male counterparts. Chin Med J (Engl) 2010;123(17): 2347-2352.
119. Ciatto S, Iossa A, Bonardi R et al. Male breast carcinoma: review of a multicenter series of 150 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Italy. Tumori 1990; 76(6): 555-558.
120. Yildirim E, Berberoglu U. Male breast cancer: a 22-year experience. Eur J Surg Oncol 1998; 24(6): 548-552.
121. Tajima N, Tsukuma H, Oshima A. Descriptive epidemiology of male breast cancer in Osaka, Japan. J Epidemiol 2001; 11(1): 1-7.
122. Gnerlich JL, Deshpande AD, Jeffe DB et al. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to instage migration. Ann Surg Oncol 2011; 18(7): 1837-1844.
123. Rudan I, Rudan N, Basic N et al. Differences between male and female breast cancer. II. Clinicopathologic features. Acta Med Croatica 1997; 51(3): 129-133.
124. Miao H, Verkooijen HM, Chia KS et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol 2011; 29(33): 4381-4386.
125. Foerster R, Foerster FG, Wulff V et al. Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC Cancer 2011; 11: 335.
126. Willsher PC, Leach IH, Ellis IO et al. A comparison outcome of male breast cancer with female breast cancer. Am J Surg 1997; 173(3): 185-188.
127. O'Malley CD, Prehn AW, Shema SJ et al. Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer 2002; 94(11): 2836-2843.
128. Crew KD, Neugut AI, Wang X et al. Racial disparities in treatment and survival of male breast cancer. J Clin Oncol 2007; 25(9): 1089-1098.
129. Hill TD, Khamis HJ, Tyczynski JE et al. Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival. Ann Epidemiol 2005; 15(10): 773-780.
130. Klein J, Ji M, Rea NK et al. Differences in male breast cancer stage, tumor size at diagnosis, and survival rate between metropolitan and nonmetropolitan regions. Am J Mens Health 2011; 5(5): 430-437.
131. Brenner B, Fried G, Levitzki P et al. Male breast carcinoma in Israel: higher incident but possibly prognosis in Ashkenazi Jews. Cancer 2002; 94(8): 2128-2133.
132. Ioka A, Tsukuma H, Ajiki W et al. Survival of male breast cancer patients: a population-based study in Osaka, Japan. Jpn J Clin Oncol 2006; 36(11): 699-703.
133. Goss PE, Reid C, Pintilie M et al. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 1999; 85(3): 629-639.
134. Adami HO, Hakulinen T, Ewertz M et al. The survival pattern in male breast cancer. An analysis of 1429 patients from the Nordic countries. Cancer 1989; 64(6): 1177-1182.
135. Frangou EM, Lawson J, Kanthan R. Angiogenesis in male breast cancer. World J Surg Oncol 2005; 3(1): 16.
136. Ngoo KS, Rohaizak M, Naqiyah I et al. Male breast cancer: experience from a Malaysian tertiary centre. Singapore Med J 2009; 50(5): 519-521.
137. Bourhafour M, Belbaraka R, Souadka A et al. Male breast cancer: a report of 127 cases at a Moroccan institution. BMC Res Notes 2011; 4: 219.
138. Sandler B, Carman C, Perry RR. Cancer of the male breast. Am Surg 1994; 60 (11): 816-820.
139. Shukla NK, Seenu V, Goel AK et al. Male breast cancer: a retrospective study from a regional cancer center in northern India. J Surg Oncol 1996; 61(2): 143-148.
140. El Omari-Alaoui H, Lahdiri I, Nejjar I et al. Male breast cancer. A report of 71 cases. Cancer Radiother 2002; 6(6): 349-351.
141. Jamal S, Mamoon N, Mushtaq S et al. Carcinoma of the male breast: a study of 141 cases from northern Pakistan. Asian Pac J Cancer Prev 2006; 7(1): 119-121.
142. Joshi MG, Lee AK, Loda M et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 1996; 77(3): 490-498.
143. McLachlan SA, Erlichman C, Liu FF et al. Male breast cancer: an 11 year review of 66 patients. Breast Cancer Res Treat 1996; 40(3): 225-230.
144. Borgen PI, Wong GY, Vlamis V et al. Current management of male breast cancer. A review of 104 cases. Ann Surg 1992; 215(5): 451-457; Discussion 457-459.
145. Hultborn R, Friberg S, Hultborn KA et al. Male breast carcinoma. II. A study of the total material reported to the Swedish Cancer Registry 1958-1967 with respect to treatment, prognostic factors and survival. Acta Oncol 1987; 26(5): 327-341.
146. Digenis AG, Ross CB, Morrison JG et al. Carcinoma of the male breast: a review of 41 cases. South Med J 1990; 83(10): 1162-1167.
147. Simon MS, McKnight E, Schwartz A et al. Racial differences in cancer of the male breast-15 year experience in the Detroit metropolitan area. Breast Cancer Res Treat 1992; 21(1): 55-62.
148. Engin K, Unsal M. Cancer of the male breast: the Turkish experience. J Surg Oncol 1993; 53(2): 128-132.
149. Gough DB, Donohue JH, Evans MM et al. A 50-year experience of male breast cancer: is outcome changing? Surg Oncol 1993; 2(6): 325-333.
150. Lartigau E, el-Jabbour JN, Dubray B et al. Male breast carcinoma: a single centre report of clinical parameters. Clin Oncol (R Coll Radiol) 1994; 6(3): 162-166.
151. Stierer M, Rosen H, Weitensfelder W et al. Male breast cancer: Austrian experience. World J Surg 1995; 19(5): 687-692; Discussion 692-683.
152. Cutuli B, Lacroze M, Dilhuydy JM et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 1995; 31A(12): 1960-1964.
153. Rudan I, Rudan N, Basic N et al. Differences between male and female breast cancer. III. Prognostic features. Acta Med Croatica 1997; 51(3): 135-141.
154. Hill AD, Borgen PI, Cody HS, III. Sentinel node biopsy in male breast cancer. Eur J Surg Oncol 1999; 25(4): 442-443.
155. Herman K, Lobaziewicz W, Skotnicki P et al. Male breast cancer. Does the prognosis differ compared to female? Neoplasma 2000; 47(3): 191-195.
156. Andre S, Fonseca I, Pinto AE et al. Male breast cancer-a reappraisal of clinical and biologic indicators of prognosis. Acta Oncol 2001; 40(4): 472-478.
157. Serra C, Vizoso F, Alonso L et al. Expression and prognostic significance of lysozyme in male breast cancer. Breast Cancer Res 2002; 4(6): R16.
158. Atalay C, Kanlioz M, Altinok M. Prognostic factors affecting survival in male breast cancer. J Exp Clin Cancer Res 2003; 22(1): 29-33.
159. Temmim L, Luqmani YA, Jarallah M et al. Evaluation of prognostic factors in male breast cancer. Breast 2001; 10(2): 166-175.
160. Yoney A, Kucuk A, Alan O et al. A retrospective study of treatment and outcome in 39 cases of male breast cancer. Hematol Oncol Stem Cell Ther 2008; 1(2): 98-105.
161. Cutuli B, Le-Nir CC, Serin D et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol 2010; 73(3): 246-254.
162. Zhou FF, Xia LP, Wang X et al. Analysis of prognostic factors in male breast cancer: a report of 72 cases from a single institution. Chin J Cancer 2010; 29 (2): 184-188.
163. Hittmair AP, Lininger RA, Tavassoli FA. Ductal carcinoma in situ (DCIS) in the male breast: a morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma-a preliminary report. Cancer 1998; 83(10): 2139-2149.
164. Cutuli B. Strategies in treating male breast cancer. Expert Opin Pharmacother 2007; 8(2): 193-202.
165. Anderson WF, Devesa SS. In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute. Cancer 2005; 104(8): 1733-1741.
166. Pich A, Margaria E, Chiusa L et al. DNA ploidy and p53 expression correlate with survival and cell proliferative activity in male breast carcinoma. Hum Pathol 1996; 27(7): 676-682.
167. Chiusa L, Margaria E, Pich A. Nuclear morphometry in male breast carcinoma: association with cell proliferative activity, oncogene expression, DNA content and prognosis. Int J Cancer 2000; 89(6): 494-499.
168. Pich A, Margaria E, Chiusa L. Proliferative activity is a significant prognostic factor in male breast carcinoma. Am J Pathol 1994; 145(2): 481-489.
169. Blin N, Kardas I, Welter C et al. Expression of the c-erbB2 proto-oncogene in male breast carcinoma: lack of prognostic significance. Oncology 1993; 50(6): 408-411.
170. Shpitz B, Bomstein Y, Sternberg A et al. Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer. J Surg Oncol 2000; 75(4): 252-257.
171. Mourao Netto M, Logullo AF, Nonogaki S et al. Expression of c-erbB-2, p53 and c-myc proteins in male breast carcinoma: comparison with traditional prognostic factors and survival. Braz J Med Biol Res 2001; 34(7): 887-894.
172. Idelevich E, Mozes M, Ben-Baruch N et al. Oncogenes in male breast cancer. Am J Clin Oncol 2003; 26(3): 259-261.
173. Pich A, Margaria E, Chiusa L. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. J Clin Oncol 2000; 18(16): 2948-2956.
174. Wang-Rodriguez J, Cross K, Gallagher S et al. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 2002; 15(8): 853-861.
175. Fonseca RR, Tomas AR, Andre S et al. Evaluation of ERBB2 gene status and chromosome 17 anomalies in male breast cancer. Am J Surg Pathol 2006; 30 (10): 1292-1298.
176. Meijer-van Gelder ME, Look MP, Bolt-de Vries J et al. Clinical relevance of biologic factors in male breast cancer. Breast Cancer Res Treat 2001; 68(3): 249-260.
177. de Ieso PB, Potter AE, Le H et al. Male breast cancer: a 30-year experience in South Australia. Asia Pac J Clin Oncol 2012; 8(2): 187-193.
178. Sun X, Gong Y, Rao MS et al. Loss of BRCA1 expression in sporadic male breast carcinoma. Breast Cancer Res Treat 2002; 71(1): 1-7.
179. Anderson J, Reddy VB, Green L et al. Role of expression of cell cycle inhibitor p27 and MIB-1 in predicting lymph node metastasis in male breast carcinoma. Breast J 2002; 8(2): 101-107.
180. Kanthan R, Fried I, Rueckl T et al. Expression of cell cycle proteins in male breast carcinoma. World J Surg Oncol 2010; 8: 10.
181. Kwiatkowska E, Teresiak M, Filas V et al. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res 2003; 9(12): 4452-4459.
182. Dakin Hache K, Gray S, Barnes PJ et al. Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat 2007; 105(2): 169-175.
183. Younis T, Hache KD, Rayson D et al. Survivin and COX-2 expression in male breast carcinoma. Breast 2009; 18(4): 228-232.
184. Kornegoor R, Verschuur-Maes AH, Buerger H et al. Fibrotic focus and hypoxia in male breast cancer. Mod Pathol 2012; 25(10): 1397-1404.
185. Ottini L, Silvestri V, Rizzolo P et al. Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Res Treat 2012; 21(3): 296-302.
186. Doyle S, Steel J, Porter G. Imaging male breast cancer. Clin Radiol 2011; 66 (11): 1079-1085.
187. Sneige N, Holder PD, Katz RL et al. Fine-needle aspiration cytology of the male breast in a cancer center. Diagn Cytopathol 1993; 9(6): 691-697.
188. Zhou FF, Xia LP, Guo GF et al. Changes in therapeutic strategies in Chinese male patients with breast cancer: 40 years of experience in a single institute. Breast 2010; 19(6): 450-455.
189. Schaub NP, Maloney N, Schneider H et al. Changes in male breast cancer over a 30-year period. Am Surg 2008; 74(8): 707-711; Discussion 711-702.
190. Scott-Conner CE, Jochimsen PR, Menck HR et al. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery 1999; 126(4): 775-780; Discussion 780-771.
191. Gentilini O, Chagas E, Zurrida S et al. Sentinel lymph node biopsy in male patients with early breast cancer. Oncologist 2007; 12(5): 512-515.
192. Boughey JC, Bedrosian I, Meric-Bernstam F et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg 2006; 203(4): 475-480.
193. Flynn LW, Park J, Patil SM et al. Sentinel lymph node biopsy is successful and accurate in male breast carcinoma. J Am Coll Surg 2008; 206(4): 616-621.
194. Chakravarthy A, Kim CR. Post-mastectomy radiation in male breast cancer. Radiother Oncol 2002; 65(2): 99-103.
195. Bratman SV, Kapp DS, Horst KC. Evolving trends in the initial locoregional management of male breast cancer. Breast 2012; 21(3): 296-302.
196. Stranzl H, Mayer R, Quehenberger F et al. Adjuvant radiotherapy in male breast cancer. Radiother Oncol 1999; 53(1): 29-35.
197. Yu E, Suzuki H, Younus J et al. The impact of post-mastectomy radiation therapy on male breast cancer patients-a case series. Int J Radiat Oncol Biol Phys 2012; 82(2): 696-700.
198. Yoney A, Kucuk A, Unsal M. Male breast cancer: a retrospective analysis. Cancer Radiother 2009; 13(2): 103-107.
199. Atahan L, Yildiz F, Selek U et al. Postoperative radiotherapy in the treatment of male breast carcinoma: a single institute experience. J Natl Med Assoc 2006; 98(4): 559-563.
200. Ihekwaba FN. The management of male breast cancer in Nigerians. Postgrad Med J 1993; 69(813): 562-565.
201. Margaria E, Chiusa L, Ferrari L et al. Therapy and survival in male breast carcinoma: a retrospective analysis of 50 cases. Oncol Rep 2000; 7(5): 1035-1039.
202. Giordano SH, Perkins GH, Broglio K et al. Adjuvant systemic therapy for male breast carcinoma. Cancer 2005; 104(11): 2359-2364.
203. Fogh S, Hirsch AE, Langmead JP et al. Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer. Clin Breast Cancer 2011; 11(1): 39-45.
204. Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 1992; 65(2): 252-254.
205. Izquierdo MA, Alonso C, De Andres L et al. Male breast cancer. Report of a series of 50 cases. Acta Oncol 1994; 33(7): 767-771.
206. Anelli TF, Anelli A, Tran KN et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 1994; 74(1): 74-77.
207. Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol 2010; 17(5): 17-21.
208. Pemmaraju N, Munsell MF, Hortobagyi GN et al. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Ann Oncol 2012; 23(6): 1471-1474.
209. Andrykowski MA. Physical and mental health status and health behaviors in male breast cancer survivors: a national, population-based, case-control study. Psychooncology 2011; 21(9): 927-934.
210. Kowalski C, Steffen P, Ernstmann N et al. Health-related quality of life in male breast cancer patients. Breast Cancer Res Treat 2012; 133(2): 753-757.
211. Hemminki K, Scelo G, Boffetta P et al. Second primary malignancies in patients with male breast cancer. Br J Cancer 2005; 92(7): 1288-1292.
212. Lee UJ, Jones JS. Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening. Prostate Cancer Prostatic Dis 2009; 12(1): 52-56.
213. Zanna I, Rizzolo P, Sera F et al. The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases. Eur J Hum Genet 2010; 18(7): 856-858.
214. Storm HH, Olsen J. Risk of breast cancer in offspring of male breast-cancer patients. Lancet 1999; 353(9148): 209.
215. Anderson DE, Badzioch MD. Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst 1992; 84(14): 1114-1117.
216. Hemminki K, Vaittinen P. Male breast cancer: risk to daughters. Lancet 1999; 353(9159): 1186-1187.
217. Hultborn R, Friberg S, Hultborn KA. Male breast carcinoma. I. A study of the total material reported to the Swedish Cancer Registry 1958-1967 with respect to clinical and histopathologic parameters. Acta Oncol 1987; 26(4): 241-256.
218. Rudan I, Rudan N, Strnad M. Differences between male and female breast cancer. I. Epidemiological features. Acta Med Croatica 1995; 49(3): 117-120.
219. Kuroishi T, Hirose K, Tajima K et al. Descriptive epidemiology of male breast cancer in Japan. Breast Cancer 1997; 4(2): 77-83.
220. Ron E, Ikeda T, Preston DL et al. Male breast cancer incidence among atomic bomb survivors. J Natl Cancer Inst 2005; 97(8): 603-605.
221. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006; 367(9510): 595-604.
222. Sorensen HT, Olsen ML, Mellemkjaer L et al. The intrauterine origin of male breast cancer: a birth order study in Denmark. Eur J Cancer Prev 2005; 14(2): 185-186.